| Field | Row 1 |
|---|---|
| adsh | 0000950170-25-069824 |
| cik | 1835022 |
| name | COYA THERAPEUTICS, INC. |
| sic | 2834 |
| countryba | US |
| stprba | TX |
| cityba | HOUSTON |
| zipba | 77024 |
| bas1 | 12645 MEMORIAL DR., SUITE F1 #305 |
| bas2 | |
| baph | 650.739.3939 |
| countryma | US |
| stprma | TX |
| cityma | HOUSTON |
| zipma | 77024 |
| mas1 | 12645 MEMORIAL DR., SUITE F1 #305 |
| mas2 | |
| countryinc | US |
| stprinc | DE |
| ein | 000000000 |
| former | |
| changed | |
| afs | 4-NON |
| wksi | 0 |
| fye | 1231 |
| form | 10-Q |
| period | 20250331 |
| fy | 2025 |
| fp | Q1 |
| filed | 20250513 |
| accepted | 2025-05-13 08:15:00.0 |
| prevrpt | 0 |
| detail | 1 |
| instance | coya-20250331_htm.xml |
| nciks | 1 |
| aciks |
| Field Name | Field Description |
|---|---|
| adsh | Accession Number. The 20-character string formed from the 18-digit number assigned by the SEC to each EDGAR submission. |
| cik | Central Index Key (CIK). Ten digit number assigned by the SEC to each registrant that submits filings. |
| name | Name of registrant. This corresponds to the name of the legal entity as recorded in EDGAR as of the filing date. |
| sic | Standard Industrial Classification (SIC). Four digit code assigned by the SEC as of the filing date, indicating the registrant’s type of business. |
| countryba | The ISO 3166-1 country of the registrant's business address. |
| stprba | The state or province of the registrant’s business address, if field countryba is US or CA. |
| cityba | The city of the registrant's business address. |
| zipba | The zip code of the registrant’s business address. |
| bas1 | The first line of the street of the registrant’s business address. |
| bas2 | The second line of the street of the registrant’s business address. |
| baph | The phone number of the registrant’s business address. |
| countryma | The ISO 3166-1 country of the registrant's mailing address. |
| stprma | The state or province of the registrant’s mailing address, if field countryma is US or CA. |
| cityma | The city of the registrant's mailing address. |
| zipma | The zip code of the registrant’s mailing address. |
| mas1 | The first line of the street of the registrant’s mailing address. |
| mas2 | The second line of the street of the registrant’s mailing address. |
| countryinc | The ISO 3166-1 country of incorporation for the registrant. |
| stprinc | The state or province of incorporation for the registrant, if countryinc is US or CA. |
| ein | Employee Identification Number, 9 digit identification number assigned by the Internal Revenue Service to business entities operating in the United States. |
| former | Most recent former name of the registrant, if any. |
| changed | Date of change from the former name, if any. |
| afs | Filer status with the SEC at the time of submission: 1-LAF=Large Accelerated, 2-ACC=Accelerated, 3-SRA=Smaller Reporting Accelerated, 4-NON=Non-Accelerated, 5-SML=Smaller Reporting Filer, NULL=not assigned. |
| wksi | Well Known Seasoned Issuer (WKSI). An issuer that meets specific SEC requirements at some point during a 60-day period preceding the date the issuer satisfies its obligation to update its shelf registration statement. |
| fye | Fiscal Year End Date, rounded to nearest month-end. |
| form | The submission type of the registrant’s filing. |
| period | Balance Sheet Date, rounded to nearest month-end. |
| fy | Fiscal Year Focus (as defined in the EDGAR XBRL Guide Ch. 3.1.8). |
| fp | Fiscal Period Focus (as defined in the EDGAR XBRL Guide Ch. 3.1.8) within Fiscal Year. |
| filed | The date of the registrant’s filing with the Commission. |
| accepted | The acceptance date and time of the registrant’s filing with the Commission. |
| prevrpt | Previous Report – TRUE indicates that the submission information was subsequently amended. |
| detail | TRUE indicates that the XBRL submission contains quantitative disclosures within the footnotes and schedules at the required detail level (e.g., each amount). |
| instance | The name of the submitted XBRL Instance Document. The name often begins with the company ticker symbol. |
| nciks | Number of Central Index Keys (CIK) of registrants (i.e., business units) included in the consolidating entity’s submitted filing. |
| aciks | Additional CIKs of co-registrants included in a consolidating entity’s EDGAR submission, separated by spaces. If there are no other co-registrants (i.e., nciks=1), the value of aciks is NULL. For a very small number of filers, the entire list of co-registrants is too long to fit in the field. Where this is the case, users should refer to the complete submission file for all CIK information. |
| adsh | ddate | tag | value | uom | qtrs | version | segments | coreg | footnote |
|---|---|---|---|---|---|---|---|---|---|
| 0000950170-25-069824 | 20241231 | Accounts Payable Current | 1588128.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-069824 | 20241231 | Accrued Liabilities Current | 1388060.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-069824 | 20250331 | Accrued Liabilities Current | 1809583.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-069824 | 20240331 | Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | 435663.0000 | USD | 1 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0000950170-25-069824 | 20241231 | Cash And Cash Equivalents At Carrying Value | 38339762.0000 | USD | 0 | us-gaap/2024 | Fair Value By Fair Value Hierarchy Level= Fair Value Inputs Level1; Fair Value By Measurement Frequency= Fair Value Measurements Recurring; | ||
| 0000950170-25-069824 | 20250331 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect | -2809138.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-069824 | 20241231 | Common Stock Shares Authorized | 200000000.0000 | shares | 0 | us-gaap/2024 | |||
| 0000950170-25-069824 | 20240331 | Exercise Value Of Warrants | 1360457.0000 | USD | 1 | 0000950170-25-069824 | |||
| 0000950170-25-069824 | 20240331 | General And Administrative Expense | 2439841.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-069824 | 20240331 | Increase Decrease In Deferred Revenue | -126838.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-069824 | 20240331 | In Process Research And Development | 25000.0000 | USD | 1 | 0000950170-25-069824 | |||
| 0000950170-25-069824 | 20240331 | Operating Income Loss | -5483002.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-069824 | 20250331 | Operating Income Loss | -7676922.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-069824 | 20240331 | Payment Of Financing Costs Related To Private Placement | 131918.0000 | USD | 1 | 0000950170-25-069824 | |||
| 0000950170-25-069824 | 20250331 | Preferred Stock Shares Authorized | 10000000.0000 | shares | 0 | us-gaap/2024 | |||
| 0000950170-25-069824 | 20250331 | Preferred Stock Shares Outstanding | 0.0000 | shares | 0 | us-gaap/2024 | |||
| 0000950170-25-069824 | 20241231 | Property Plant And Equipment Net | 38588.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-069824 | 20240331 | Research And Development Expense Excluding Acquired In Process Cost | 540884.0000 | USD | 1 | us-gaap/2024 | Income Statement Location= Internal Research And Development Expenses Including Stock- Based Compensation; | ||
| 0000950170-25-069824 | 20240331 | Research And Development Expense Excluding Acquired In Process Cost | 101986.0000 | USD | 1 | us-gaap/2024 | Income Statement Location= Sponsored Research; | ||
| 0000950170-25-069824 | 20240331 | Revenues | 126838.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-069824 | 20250331 | Share Based Compensation | 1080082.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-069824 | 20250331 | Shares Outstanding | 16724998.0000 | shares | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0000950170-25-069824 | 20231231 | Stockholders Equity | -25856383.0000 | USD | 0 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0000950170-25-069824 | 20241231 | Stockholders Equity | -40737170.0000 | USD | 0 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0000950170-25-069824 | 20250331 | Stockholders Equity | 33369557.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-069824 | 20250331 | Stock Issued During Period Shares Stock Options Exercised | 17557.0000 | shares | 1 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0000950170-25-069824 | 20250331 | Stock Issued During Period Value Stock Options Exercised | 19135.0000 | USD | 1 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0000950170-25-069824 | 20250331 | Stock Issued During Period Value Stock Options Exercised | 2.0000 | USD | 1 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0000950170-25-069824 | 20240331 | Subscription Receivable In Value | 11250.0000 | USD | 1 | 0000950170-25-069824 | Equity Components= Receivables From Stockholder; | ||
| 0000950170-25-069824 | 20240331 | Subscription Receivable Related To Warrant Exercise | 149250.0000 | USD | 1 | 0000950170-25-069824 | |||
| 0000950170-25-069824 | 20250331 | Property Plant And Equipment Net | 31748.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-069824 | 20240331 | Research And Development Expense Excluding Acquired In Process Cost | 3138159.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-069824 | 20231231 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | 32626768.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-069824 | 20240331 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect | 3362638.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-069824 | 20250331 | Common Stock Shares Issued | 16724998.0000 | shares | 0 | us-gaap/2024 | |||
| 0000950170-25-069824 | 20240331 | Exercise Of Warrants | 206018.0000 | shares | 1 | 0000950170-25-069824 | Equity Components= Common Stock; | ||
| 0000950170-25-069824 | 20240331 | Income Tax Expense Benefit | USD | 1 | us-gaap/2024 | ||||
| 0000950170-25-069824 | 20250331 | Increase Decrease In Accounts Payable | 101879.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-069824 | 20241231 | Liabilities | 4769921.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-069824 | 20250331 | Liabilities And Stockholders Equity | 38404996.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-069824 | 20250331 | Net Cash Provided By Used In Operating Activities | -2828275.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-069824 | 20250331 | Net Income Loss | -7306757.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-069824 | 20241231 | Preferred Stock Par Or Stated Value Per Share | 0.0001 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-069824 | 20250331 | Profit Loss | -7306757.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-069824 | 20240331 | Stockholders Equity | -149250.0000 | USD | 0 | us-gaap/2024 | Equity Components= Receivables From Stockholder; | ||
| 0000950170-25-069824 | 20240331 | Stockholders Equity | -30908296.0000 | USD | 0 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0000950170-25-069824 | 20240331 | Subscription Receivable In Value | 11250.0000 | USD | 1 | 0000950170-25-069824 | |||
| 0000950170-25-069824 | 20240331 | Weighted Average Number Of Diluted Shares Outstanding | 14457839.0000 | shares | 1 | us-gaap/2024 | |||
| 0000950170-25-069824 | 20250331 | Cash And Cash Equivalents At Carrying Value | 35530624.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-069824 | 20250331 | Cash And Cash Equivalents At Carrying Value | 35530624.0000 | USD | 0 | us-gaap/2024 | Fair Value By Fair Value Hierarchy Level= Fair Value Inputs Level1; Fair Value By Measurement Frequency= Fair Value Measurements Recurring; | ||
| 0000950170-25-069824 | 20241231 | Commitments And Contingencies | USD | 0 | us-gaap/2024 | ||||
| 0000950170-25-069824 | 20250331 | Common Stock Value | 1673.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-069824 | 20250331 | General And Administrative Expense | 2713890.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-069824 | 20250331 | Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | -7306757.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-069824 | 20240331 | Increase Decrease In Collaboration Receivable | -7500000.0000 | USD | 1 | 0000950170-25-069824 | |||
| 0000950170-25-069824 | 20250331 | Increase Decrease In Deferred Revenue | -257884.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-069824 | 20240331 | Net Cash Provided By Used In Operating Activities | 2145874.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-069824 | 20250331 | Net Income Loss | -7306757.0000 | USD | 1 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0000950170-25-069824 | 20240331 | Payments To Acquire In Process Research And Development | 25000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-069824 | 20250331 | Prepaid Expense And Other Assets Current | 2842624.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-069824 | 20240331 | Proceeds From Stock Options Exercised | 1975.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-069824 | 20250331 | Research And Development Expense Excluding Acquired In Process Cost | 4022376.0000 | USD | 1 | us-gaap/2024 | Income Statement Location= Preclinical Product Candidates; | ||
| 0000950170-25-069824 | 20241231 | Retained Earnings Accumulated Deficit | -40737170.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-069824 | 20250331 | Retained Earnings Accumulated Deficit | -48043927.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-069824 | 20240331 | Share Based Compensation | 435663.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-069824 | 20231231 | Stockholders Equity | 35635609.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-069824 | 20231231 | Stockholders Equity | 61501801.0000 | USD | 0 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0000950170-25-069824 | 20240331 | Stockholders Equity | 32393041.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-069824 | 20240331 | Stockholders Equity | 1462.0000 | USD | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0000950170-25-069824 | 20241231 | Stockholders Equity | 1671.0000 | USD | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0000950170-25-069824 | 20250331 | Stock Issued During Period Shares Stock Options Exercised | 17557.0000 | shares | 1 | us-gaap/2024 | |||
| 0000950170-25-069824 | 20240331 | Stock Issued During Period Value Stock Options Exercised | 1975.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-069824 | 20250331 | Preferred Stock Value | USD | 0 | us-gaap/2024 | ||||
| 0000950170-25-069824 | 20240331 | Net Cash Provided By Used In Investing Activities | -25000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-069824 | 20250331 | Other Nonoperating Income Expense | 370165.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-069824 | 20250331 | Additional Paid In Capital | 81411811.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-069824 | 20250331 | Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | 1080082.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-069824 | 20241231 | Assets | 44347016.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-069824 | 20241231 | Assets Current | 44308428.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-069824 | 20241231 | Common Stock Shares Issued | 16707441.0000 | shares | 0 | us-gaap/2024 | |||
| 0000950170-25-069824 | 20250331 | Common Stock Shares Outstanding | 16724998.0000 | shares | 0 | us-gaap/2024 | |||
| 0000950170-25-069824 | 20250331 | Deferred Collaboration Revenue | 694435.0000 | USD | 0 | 0000950170-25-069824 | |||
| 0000950170-25-069824 | 20241231 | Deferred Revenue Current | 848286.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-069824 | 20240331 | Earnings Per Share Basic | -0.3500 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-069824 | 20240331 | Earnings Per Share Diluted | -0.3500 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-069824 | 20250331 | Income Tax Expense Benefit | USD | 1 | us-gaap/2024 | ||||
| 0000950170-25-069824 | 20250331 | Proceeds From Stock Options Exercised | 19137.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-069824 | 20240331 | Research And Development Expense Excluding Acquired In Process Cost | 2495289.0000 | USD | 1 | us-gaap/2024 | Income Statement Location= Preclinical Product Candidates; | ||
| 0000950170-25-069824 | 20250331 | Research And Development Expense Excluding Acquired In Process Cost | 5214076.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-069824 | 20250331 | Research And Development Expense Excluding Acquired In Process Cost | 202410.0000 | USD | 1 | us-gaap/2024 | Income Statement Location= Sponsored Research; | ||
| 0000950170-25-069824 | 20231231 | Shares Outstanding | 14405325.0000 | shares | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0000950170-25-069824 | 20250331 | Stockholders Equity | 81411811.0000 | USD | 0 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0000950170-25-069824 | 20250331 | Deferred Collaboration Revenue | 1500000.0000 | USD | 0 | 0000950170-25-069824 | Type Of Arrangement= Drl Development Agreement; | ||
| 0000950170-25-069824 | 20250331 | Deferred Revenue Current | 841414.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-069824 | 20250331 | Deferred Revenue Current | 800000.0000 | USD | 0 | us-gaap/2024 | Type Of Arrangement= Drl Development Agreement; | ||
| 0000950170-25-069824 | 20250331 | Common Stock Par Or Stated Value Per Share | 0.0001 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-069824 | 20241231 | Common Stock Value | 1671.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-069824 | 20240331 | Exercise Value Of Warrants | 21.0000 | USD | 1 | 0000950170-25-069824 | Equity Components= Common Stock; | ||
| 0000950170-25-069824 | 20250331 | Liabilities | 5035439.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-069824 | 20250331 | Liabilities Current | 4341004.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-069824 | 20250331 | Operating Expenses | 7934806.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-069824 | 20240331 | Other Nonoperating Income Expense | 431089.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-069824 | 20241231 | Stockholders Equity | 80312594.0000 | USD | 0 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0000950170-25-069824 | 20250331 | Stockholders Equity | -48043927.0000 | USD | 0 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0000950170-25-069824 | 20250331 | Accounts Payable Current | 1690007.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-069824 | 20240331 | Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | 435663.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-069824 | 20250331 | Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | 1080082.0000 | USD | 1 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0000950170-25-069824 | 20250331 | Assets Current | 38373248.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-069824 | 20250331 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | 35530624.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-069824 | 20250331 | Common Stock Shares Authorized | 200000000.0000 | shares | 0 | us-gaap/2024 | |||
| 0000950170-25-069824 | 20250331 | Earnings Per Share Basic | -0.4400 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-069824 | 20240331 | Exercise Value Of Warrants | 1509686.0000 | USD | 1 | 0000950170-25-069824 | Equity Components= Additional Paid In Capital; | ||
| 0000950170-25-069824 | 20240331 | Exercise Value Of Warrants | -149250.0000 | USD | 1 | 0000950170-25-069824 | Equity Components= Receivables From Stockholder; | ||
| 0000950170-25-069824 | 20240331 | Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | -5051913.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-069824 | 20240331 | Increase Decrease In Accounts Payable | 477265.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-069824 | 20250331 | Increase Decrease In Prepaid Deferred Expense And Other Assets | -3126042.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-069824 | 20240331 | Net Income Loss | -5051913.0000 | USD | 1 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0000950170-25-069824 | 20241231 | Preferred Stock Shares Authorized | 10000000.0000 | shares | 0 | us-gaap/2024 | |||
| 0000950170-25-069824 | 20241231 | Preferred Stock Shares Issued | 0.0000 | shares | 0 | us-gaap/2024 | |||
| 0000950170-25-069824 | 20241231 | Preferred Stock Shares Outstanding | 0.0000 | shares | 0 | us-gaap/2024 | |||
| 0000950170-25-069824 | 20241231 | Prepaid Expense And Other Assets Current | 5968666.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-069824 | 20240331 | Profit Loss | -5051913.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-069824 | 20250331 | Research And Development Expense Excluding Acquired In Process Cost | 989290.0000 | USD | 1 | us-gaap/2024 | Income Statement Location= Internal Research And Development Expenses Including Stock- Based Compensation; | ||
| 0000950170-25-069824 | 20250331 | Revenues | 257884.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-069824 | 20240331 | Shares Outstanding | 14613172.0000 | shares | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0000950170-25-069824 | 20231231 | Stockholders Equity | 1441.0000 | USD | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0000950170-25-069824 | 20241231 | Stockholders Equity | 39577095.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-069824 | 20250331 | Weighted Average Number Of Diluted Shares Outstanding | 16720511.0000 | shares | 1 | us-gaap/2024 | |||
| 0000950170-25-069824 | 20240331 | Weighted Average Number Of Shares Outstanding Basic | 14457839.0000 | shares | 1 | us-gaap/2024 | |||
| 0000950170-25-069824 | 20240331 | Stock Issued During Period Value Stock Options Exercised | 1975.0000 | USD | 1 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0000950170-25-069824 | 20250331 | Weighted Average Number Of Shares Outstanding Basic | 16720511.0000 | shares | 1 | us-gaap/2024 | |||
| 0000950170-25-069824 | 20241231 | Additional Paid In Capital | 80312594.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-069824 | 20250331 | Assets | 38404996.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-069824 | 20241231 | Common Stock Shares Outstanding | 16707441.0000 | shares | 0 | us-gaap/2024 | |||
| 0000950170-25-069824 | 20240331 | Depreciation | 6840.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-069824 | 20250331 | Earnings Per Share Diluted | -0.4400 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-069824 | 20240331 | Increase Decrease In Prepaid Deferred Expense And Other Assets | 275398.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-069824 | 20241231 | Liabilities And Stockholders Equity | 44347016.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-069824 | 20240331 | Net Cash Provided By Used In Financing Activities | 1241764.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-069824 | 20240331 | Net Income Loss | -5051913.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-069824 | 20250331 | Preferred Stock Shares Issued | 0.0000 | shares | 0 | us-gaap/2024 | |||
| 0000950170-25-069824 | 20240331 | Proceeds From Subscription Receivable | 11250.0000 | USD | 1 | 0000950170-25-069824 | |||
| 0000950170-25-069824 | 20241231 | Shares Outstanding | 16707441.0000 | shares | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0000950170-25-069824 | 20240331 | Stockholders Equity | 63449125.0000 | USD | 0 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0000950170-25-069824 | 20250331 | Stockholders Equity | 1673.0000 | USD | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0000950170-25-069824 | 20241231 | Cash And Cash Equivalents At Carrying Value | 38339762.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-069824 | 20240331 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | 35989406.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-069824 | 20241231 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | 38339762.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-069824 | 20250331 | Commitments And Contingencies | USD | 0 | us-gaap/2024 | ||||
| 0000950170-25-069824 | 20241231 | Common Stock Par Or Stated Value Per Share | 0.0001 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-069824 | 20241231 | Deferred Collaboration Revenue | 945447.0000 | USD | 0 | 0000950170-25-069824 | |||
| 0000950170-25-069824 | 20250331 | Depreciation | 6840.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-069824 | 20240331 | Increase Decrease In Accrued Liabilities | -844745.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-069824 | 20250331 | Increase Decrease In Accrued Liabilities | 421523.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-069824 | 20241231 | Liabilities Current | 3824474.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-069824 | 20250331 | Net Cash Provided By Used In Financing Activities | 19137.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-069824 | 20240331 | Operating Expenses | 5609840.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-069824 | 20250331 | Preferred Stock Par Or Stated Value Per Share | 0.0001 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-069824 | 20241231 | Preferred Stock Value | USD | 0 | us-gaap/2024 | ||||
| 0000950170-25-069824 | 20240331 | Proceeds From Warrant Exercises | 1360457.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-069824 | 20231231 | Stockholders Equity | -11250.0000 | USD | 0 | us-gaap/2024 | Equity Components= Receivables From Stockholder; | ||
| 0000950170-25-069824 | 20240331 | Stock Issued During Period Shares Stock Options Exercised | 1829.0000 | shares | 1 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0000950170-25-069824 | 20250331 | Stock Issued During Period Value Stock Options Exercised | 19137.0000 | USD | 1 | us-gaap/2024 |
| Field Name | Field Description |
|---|---|
| adsh | Accession Number. The 20-character string formed from the 18-digit number assigned by the SEC to each EDGAR submission. |
| tag | The unique identifier (name) for a tag in a specific taxonomy release. |
| version | For a standard tag, an identifier for the taxonomy; otherwise the accession number where the tag was defined. |
| ddate | The end date for the data value, rounded to the nearest month end. |
| qtrs | The count of the number of quarters represented by the data value, rounded to the nearest whole number. “0” indicates it is a point-in-time value. |
| uom | The unit of measure for the value. |
| segments | Tags used to represent axis and member reporting. |
| coreg | If specified, indicates a specific co-registrant, the parent company, or other entity (e.g., guarantor). NULL indicates the consolidated entity. |
| value | The value. This is not scaled, it is as found in the Interactive Data file, but is limited to four digits to the right of the decimal point. |
| footnote | The text of any superscripted footnotes on the value, as shown on the statement page, truncated to 512 characters, or if there is no footnote, then this field will be blank. |
| tag | version | custom | abstract | datatype | iord | crdr | tlabel | doc |
|---|---|---|---|---|---|---|---|---|
| Stock Issued During Period Value Stock Options Exercised | us-gaap/2024 | 0 | 0 | monetary | D | C | Stock Issued During Period, Value, Stock Options Exercised | Value of stock issued as a result of the exercise of stock options. |
| Assets Current | us-gaap/2024 | 0 | 0 | monetary | I | D | Assets, Current | Amount of asset recognized for present right to economic benefit, classified as current. |
| In Process Research And Development | 0000950170-25-069824 | 1 | 0 | monetary | D | D | In-process Research And Development | In-process research and development. |
| Exercise Value Of Warrants | 0000950170-25-069824 | 1 | 0 | monetary | D | C | Exercise Value of Warrants | Exercise value of warrants. |
| Deferred Revenue Current | us-gaap/2024 | 0 | 0 | monetary | I | C | Deferred Revenue, Current | Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current. |
| Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | us-gaap/2024 | 0 | 0 | monetary | D | C | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest | Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. |
| Liabilities | us-gaap/2024 | 0 | 0 | monetary | I | C | Liabilities | Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others. |
| Liabilities And Stockholders Equity | us-gaap/2024 | 0 | 0 | monetary | I | C | Liabilities and Equity | Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. |
| Proceeds From Stock Options Exercised | us-gaap/2024 | 0 | 0 | monetary | D | D | Proceeds from Stock Options Exercised | Amount of cash inflow from exercise of option under share-based payment arrangement. |
| Retained Earnings Accumulated Deficit | us-gaap/2024 | 0 | 0 | monetary | I | C | Retained Earnings (Accumulated Deficit) | Amount of accumulated undistributed earnings (deficit). |
| Increase Decrease In Collaboration Receivable | 0000950170-25-069824 | 1 | 0 | monetary | D | C | Increase (Decrease) in Collaboration Receivable | Increase (Decrease) in collaboration receivable. |
| Additional Paid In Capital | us-gaap/2024 | 0 | 0 | monetary | I | C | Additional Paid in Capital | Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock. |
| Common Stock Par Or Stated Value Per Share | us-gaap/2024 | 0 | 0 | perShare | I | Common Stock, Par or Stated Value Per Share | Face amount or stated value per share of common stock. | |
| Common Stock Shares Outstanding | us-gaap/2024 | 0 | 0 | shares | I | Common Stock, Shares, Outstanding | Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. | |
| Income Tax Expense Benefit | us-gaap/2024 | 0 | 0 | monetary | D | D | Income Tax Expense (Benefit) | Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. |
| Net Income Loss | us-gaap/2024 | 0 | 0 | monetary | D | C | Net Income (Loss) Attributable to Parent | The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. |
| Stockholders Equity | us-gaap/2024 | 0 | 0 | monetary | I | C | Equity, Attributable to Parent | Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. |
| Weighted Average Number Of Diluted Shares Outstanding | us-gaap/2024 | 0 | 0 | shares | D | Weighted Average Number of Shares Outstanding, Diluted | The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. | |
| Payment Of Financing Costs Related To Private Placement | 0000950170-25-069824 | 1 | 0 | monetary | D | C | Payment of Financing Costs Related to Private Placement | Payment of financing costs related to private placement. |
| Assets | us-gaap/2024 | 0 | 0 | monetary | I | D | Assets | Amount of asset recognized for present right to economic benefit. |
| Common Stock Shares Issued | us-gaap/2024 | 0 | 0 | shares | I | Common Stock, Shares, Issued | Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. | |
| Earnings Per Share Diluted | us-gaap/2024 | 0 | 0 | perShare | D | Earnings Per Share, Diluted | The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. | |
| Accrued Liabilities Current | us-gaap/2024 | 0 | 0 | monetary | I | C | Accrued Liabilities, Current | Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). |
| Liabilities Current | us-gaap/2024 | 0 | 0 | monetary | I | C | Liabilities, Current | Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. |
| Preferred Stock Shares Issued | us-gaap/2024 | 0 | 0 | shares | I | Preferred Stock, Shares Issued | Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt. | |
| Research And Development Expense Excluding Acquired In Process Cost | us-gaap/2024 | 0 | 0 | monetary | D | D | Research and Development Expense (Excluding Acquired in Process Cost) | Amount of expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. |
| Cash And Cash Equivalents At Carrying Value | us-gaap/2024 | 0 | 0 | monetary | I | D | Cash and Cash Equivalents, at Carrying Value | Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. |
| Share Based Compensation | us-gaap/2024 | 0 | 0 | monetary | D | D | Share-Based Payment Arrangement, Noncash Expense | Amount of noncash expense for share-based payment arrangement. |
| Increase Decrease In Prepaid Deferred Expense And Other Assets | us-gaap/2024 | 0 | 0 | monetary | D | C | Increase (Decrease) in Prepaid Expense and Other Assets | Amount of increase (decrease) in prepaid expenses, and assets classified as other. |
| Preferred Stock Value | us-gaap/2024 | 0 | 0 | monetary | I | C | Preferred Stock, Value, Issued | Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity. |
| Profit Loss | us-gaap/2024 | 0 | 0 | monetary | D | C | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest | The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. |
| Subscription Receivable Related To Warrant Exercise | 0000950170-25-069824 | 1 | 0 | monetary | D | D | Subscription Receivable Related To Warrant Exercise | Subscription receivable related to warrant exercise. |
| Deferred Collaboration Revenue | 0000950170-25-069824 | 1 | 0 | monetary | I | C | Deferred Collaboration Revenue | Deferred collaboration revenue. |
| Subscription Receivable In Value | 0000950170-25-069824 | 1 | 0 | monetary | D | D | Subscription Receivable In Value | Subscription receivable in value. |
| Net Cash Provided By Used In Operating Activities | us-gaap/2024 | 0 | 0 | monetary | D | Net Cash Provided by (Used in) Operating Activities | Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. | |
| Operating Expenses | us-gaap/2024 | 0 | 0 | monetary | D | D | Operating Expenses | Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. |
| Operating Income Loss | us-gaap/2024 | 0 | 0 | monetary | D | C | Operating Income (Loss) | The net result for the period of deducting operating expenses from operating revenues. |
| Prepaid Expense And Other Assets Current | us-gaap/2024 | 0 | 0 | monetary | I | D | Prepaid Expense and Other Assets, Current | Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect | us-gaap/2024 | 0 | 0 | monetary | D | D | Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect | Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. |
| Common Stock Value | us-gaap/2024 | 0 | 0 | monetary | I | C | Common Stock, Value, Issued | Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. |
| General And Administrative Expense | us-gaap/2024 | 0 | 0 | monetary | D | D | General and Administrative Expense | The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. |
| Revenues | us-gaap/2024 | 0 | 0 | monetary | D | C | Revenues | Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). |
| Preferred Stock Par Or Stated Value Per Share | us-gaap/2024 | 0 | 0 | perShare | I | Preferred Stock, Par or Stated Value Per Share | Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. | |
| Accounts Payable Current | us-gaap/2024 | 0 | 0 | monetary | I | C | Accounts Payable, Current | Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). |
| Commitments And Contingencies | us-gaap/2024 | 0 | 0 | monetary | I | C | Commitments and Contingencies | Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur. |
| Common Stock Shares Authorized | us-gaap/2024 | 0 | 0 | shares | I | Common Stock, Shares Authorized | The maximum number of common shares permitted to be issued by an entity's charter and bylaws. | |
| Increase Decrease In Accounts Payable | us-gaap/2024 | 0 | 0 | monetary | D | D | Increase (Decrease) in Accounts Payable | The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. |
| Net Cash Provided By Used In Financing Activities | us-gaap/2024 | 0 | 0 | monetary | D | D | Net Cash Provided by (Used in) Financing Activities | Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. |
| Shares Outstanding | us-gaap/2024 | 0 | 0 | shares | I | Shares, Outstanding | Number of shares issued which are neither cancelled nor held in the treasury. | |
| Proceeds From Subscription Receivable | 0000950170-25-069824 | 1 | 0 | monetary | D | D | Proceeds From Subscription Receivable | Proceeds from subscription receivable. |
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | us-gaap/2024 | 0 | 0 | monetary | D | C | APIC, Share-Based Payment Arrangement, Increase for Cost Recognition | Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement. |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | us-gaap/2024 | 0 | 0 | monetary | I | D | Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations | Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. |
| Depreciation | us-gaap/2024 | 0 | 0 | monetary | D | D | Depreciation | The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation. |
| Earnings Per Share Basic | us-gaap/2024 | 0 | 0 | perShare | D | Earnings Per Share, Basic | The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. | |
| Net Cash Provided By Used In Investing Activities | us-gaap/2024 | 0 | 0 | monetary | D | D | Net Cash Provided by (Used in) Investing Activities | Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. |
| Other Nonoperating Income Expense | us-gaap/2024 | 0 | 0 | monetary | D | C | Other Nonoperating Income (Expense) | Amount of income (expense) related to nonoperating activities, classified as other. |
| Preferred Stock Shares Authorized | us-gaap/2024 | 0 | 0 | shares | I | Preferred Stock, Shares Authorized | The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. | |
| Preferred Stock Shares Outstanding | us-gaap/2024 | 0 | 0 | shares | I | Preferred Stock, Shares Outstanding | Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased. | |
| Stock Issued During Period Shares Stock Options Exercised | us-gaap/2024 | 0 | 0 | shares | D | Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period | Number of share options (or share units) exercised during the current period. | |
| Increase Decrease In Accrued Liabilities | us-gaap/2024 | 0 | 0 | monetary | D | D | Increase (Decrease) in Accrued Liabilities | The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid. |
| Increase Decrease In Deferred Revenue | us-gaap/2024 | 0 | 0 | monetary | D | D | Increase (Decrease) in Deferred Revenue | Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable. |
| Payments To Acquire In Process Research And Development | us-gaap/2024 | 0 | 0 | monetary | D | C | Payments to Acquire in Process Research and Development | The cash outflows from the purchase of net carrying value allocated to in-process research and development costs and materials acquired in a business combination. |
| Proceeds From Warrant Exercises | us-gaap/2024 | 0 | 0 | monetary | D | D | Proceeds from Warrant Exercises | The cash inflow associated with the amount received from holders exercising their stock warrants. |
| Property Plant And Equipment Net | us-gaap/2024 | 0 | 0 | monetary | I | D | Property, Plant and Equipment, Net | Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. |
| Weighted Average Number Of Shares Outstanding Basic | us-gaap/2024 | 0 | 0 | shares | D | Weighted Average Number of Shares Outstanding, Basic | Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. | |
| Exercise Of Warrants | 0000950170-25-069824 | 1 | 0 | shares | D | Exercise of Warrants | Exercise of warrants. |
| Field Name | Field Description |
|---|---|
| tag | The unique identifier (name) for a tag in a specific taxonomy release. |
| version | For a standard tag, an identifier for the taxonomy; otherwise the accession number where the tag was defined. |
| custom | 1 if tag is custom (version=adsh), 0 if it is standard. Note: This flag is technically redundant with the version and adsh columns. |
| abstract | 1 if the tag is not used to represent a numeric fact. |
| datatype | If abstract=1, then NULL, otherwise the data type (e.g., monetary) for the tag. |
| iord | If abstract=1, then NULL; otherwise, “I” if the value is a point-in time, or “D” if the value is a duration. |
| crdr | If datatype = monetary, then the tag’s natural accounting balance (debit or credit); if not defined, then NULL. |
| tlabel | If a standard tag, then the label text provided by the taxonomy, otherwise the text provided by the filer. A tag which had neither would have a NULL value here. |
| doc | The detailed definition for the tag. If a standard tag, then the text provided by the taxonomy, otherwise the text assigned by the filer. Some tags have neither, and this field is NULL. |
| adsh | report | line | stmt | inpth | rfile | tag | version | plabel | negating |
|---|---|---|---|---|---|---|---|---|---|
| 0000950170-25-069824 | 2 | 3 | BS | 0 | H | Cash And Cash Equivalents At Carrying Value | us-gaap/2024 | Cash and cash equivalents | 0 |
| 0000950170-25-069824 | 2 | 4 | BS | 0 | H | Prepaid Expense And Other Assets Current | us-gaap/2024 | Prepaids and other current assets | 0 |
| 0000950170-25-069824 | 2 | 5 | BS | 0 | H | Assets Current | us-gaap/2024 | Total current assets | 0 |
| 0000950170-25-069824 | 2 | 6 | BS | 0 | H | Property Plant And Equipment Net | us-gaap/2024 | Fixed assets, net | 0 |
| 0000950170-25-069824 | 2 | 7 | BS | 0 | H | Assets | us-gaap/2024 | Total assets | 0 |
| 0000950170-25-069824 | 2 | 10 | BS | 0 | H | Accounts Payable Current | us-gaap/2024 | Accounts payable | 0 |
| 0000950170-25-069824 | 2 | 11 | BS | 0 | H | Accrued Liabilities Current | us-gaap/2024 | Accrued expenses | 0 |
| 0000950170-25-069824 | 2 | 12 | BS | 0 | H | Deferred Revenue Current | us-gaap/2024 | Deferred collaboration revenue | 0 |
| 0000950170-25-069824 | 2 | 13 | BS | 0 | H | Liabilities Current | us-gaap/2024 | Total current liabilities | 0 |
| 0000950170-25-069824 | 2 | 14 | BS | 0 | H | Deferred Collaboration Revenue | 0000950170-25-069824 | Deferred collaboration revenue | 0 |
| 0000950170-25-069824 | 2 | 15 | BS | 0 | H | Liabilities | us-gaap/2024 | Total liabilities | 0 |
| 0000950170-25-069824 | 2 | 16 | BS | 0 | H | Commitments And Contingencies | us-gaap/2024 | Commitments and contingencies (Note 6) | 0 |
| 0000950170-25-069824 | 2 | 18 | BS | 0 | H | Preferred Stock Value | us-gaap/2024 | Series A convertible preferred stock, $0.0001 par value: 10,000,000 shares authorized, none issued or outstanding as of March 31, 2025 or December 31, 2024 | 0 |
| 0000950170-25-069824 | 2 | 19 | BS | 0 | H | Common Stock Value | us-gaap/2024 | Common stock, $0.0001 par value; 200,000,000 shares authorized; 16,724,998 and 16,707,441 shares issued and outstanding as of March 31, 2025 and December 31, 2024, respectively | 0 |
| 0000950170-25-069824 | 2 | 20 | BS | 0 | H | Additional Paid In Capital | us-gaap/2024 | Additional paid-in capital | 0 |
| 0000950170-25-069824 | 2 | 21 | BS | 0 | H | Retained Earnings Accumulated Deficit | us-gaap/2024 | Accumulated deficit | 0 |
| 0000950170-25-069824 | 2 | 22 | BS | 0 | H | Stockholders Equity | us-gaap/2024 | Total stockholders' equity | 0 |
| 0000950170-25-069824 | 2 | 23 | BS | 0 | H | Liabilities And Stockholders Equity | us-gaap/2024 | Total liabilities and stockholders' equity | 0 |
| 0000950170-25-069824 | 3 | 1 | BS | 1 | H | Preferred Stock Par Or Stated Value Per Share | us-gaap/2024 | Series A convertible preferred stock, par value | 0 |
| 0000950170-25-069824 | 3 | 2 | BS | 1 | H | Preferred Stock Shares Authorized | us-gaap/2024 | Series A convertible preferred stock, shares authorized | 0 |
| 0000950170-25-069824 | 3 | 3 | BS | 1 | H | Preferred Stock Shares Issued | us-gaap/2024 | Series A convertible preferred stock, shares issued | 0 |
| 0000950170-25-069824 | 3 | 4 | BS | 1 | H | Preferred Stock Shares Outstanding | us-gaap/2024 | Series A convertible preferred stock, shares outstanding | 0 |
| 0000950170-25-069824 | 3 | 5 | BS | 1 | H | Common Stock Par Or Stated Value Per Share | us-gaap/2024 | Common stock, par value | 0 |
| 0000950170-25-069824 | 3 | 6 | BS | 1 | H | Common Stock Shares Authorized | us-gaap/2024 | Common stock, shares authorized | 0 |
| 0000950170-25-069824 | 3 | 7 | BS | 1 | H | Common Stock Shares Issued | us-gaap/2024 | Common stock, shares issued | 0 |
| 0000950170-25-069824 | 3 | 8 | BS | 1 | H | Common Stock Shares Outstanding | us-gaap/2024 | Common stock, shares outstanding | 0 |
| 0000950170-25-069824 | 4 | 1 | IS | 0 | H | Revenues | us-gaap/2024 | Collaboration revenue | 0 |
| 0000950170-25-069824 | 4 | 3 | IS | 0 | H | Research And Development Expense Excluding Acquired In Process Cost | us-gaap/2024 | Research and development | 0 |
| 0000950170-25-069824 | 4 | 4 | IS | 0 | H | In Process Research And Development | 0000950170-25-069824 | In-process research and development | 0 |
| 0000950170-25-069824 | 4 | 5 | IS | 0 | H | General And Administrative Expense | us-gaap/2024 | General and administrative | 0 |
| 0000950170-25-069824 | 4 | 6 | IS | 0 | H | Depreciation | us-gaap/2024 | Depreciation | 0 |
| 0000950170-25-069824 | 4 | 7 | IS | 0 | H | Operating Expenses | us-gaap/2024 | Total operating expenses | 0 |
| 0000950170-25-069824 | 4 | 8 | IS | 0 | H | Operating Income Loss | us-gaap/2024 | Loss from operations | 0 |
| 0000950170-25-069824 | 4 | 10 | IS | 0 | H | Other Nonoperating Income Expense | us-gaap/2024 | Other income | 0 |
| 0000950170-25-069824 | 4 | 11 | IS | 0 | H | Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | us-gaap/2024 | Pre-tax loss | 0 |
| 0000950170-25-069824 | 4 | 12 | IS | 0 | H | Income Tax Expense Benefit | us-gaap/2024 | Income tax expense | 0 |
| 0000950170-25-069824 | 4 | 13 | IS | 0 | H | Net Income Loss | us-gaap/2024 | Net loss | 0 |
| 0000950170-25-069824 | 4 | 15 | IS | 0 | H | Earnings Per Share Basic | us-gaap/2024 | Net loss per share of common stock, basic | 0 |
| 0000950170-25-069824 | 4 | 16 | IS | 0 | H | Earnings Per Share Diluted | us-gaap/2024 | Net loss per share of common stock, diluted | 0 |
| 0000950170-25-069824 | 4 | 17 | IS | 0 | H | Weighted Average Number Of Shares Outstanding Basic | us-gaap/2024 | Weighted-average shares of common stock outstanding, basic | 0 |
| 0000950170-25-069824 | 4 | 18 | IS | 0 | H | Weighted Average Number Of Diluted Shares Outstanding | us-gaap/2024 | Weighted-average shares of common stock outstanding, diluted | 0 |
| 0000950170-25-069824 | 5 | 18 | EQ | 0 | H | Stockholders Equity | us-gaap/2024 | Balance | 0 |
| 0000950170-25-069824 | 5 | 19 | EQ | 0 | H | Shares Outstanding | us-gaap/2024 | Beginning balance, shares | 0 |
| 0000950170-25-069824 | 5 | 20 | EQ | 0 | H | Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | us-gaap/2024 | Stock-based compensation expense | 0 |
| 0000950170-25-069824 | 5 | 21 | EQ | 0 | H | Stock Issued During Period Value Stock Options Exercised | us-gaap/2024 | Exercise of stock options | 0 |
| 0000950170-25-069824 | 5 | 22 | EQ | 0 | H | Stock Issued During Period Shares Stock Options Exercised | us-gaap/2024 | Exercise of stock options (in shares) | 0 |
| 0000950170-25-069824 | 5 | 23 | EQ | 0 | H | Subscription Receivable In Value | 0000950170-25-069824 | Proceeds from subscription receivable | 0 |
| 0000950170-25-069824 | 5 | 24 | EQ | 0 | H | Exercise Value Of Warrants | 0000950170-25-069824 | Exercise of warrants | 0 |
| 0000950170-25-069824 | 5 | 25 | EQ | 0 | H | Exercise Of Warrants | 0000950170-25-069824 | Exercise of warrants (in shares) | 0 |
| 0000950170-25-069824 | 5 | 26 | EQ | 0 | H | Net Income Loss | us-gaap/2024 | Net Income (Loss) | 0 |
| 0000950170-25-069824 | 5 | 27 | EQ | 0 | H | Stockholders Equity | us-gaap/2024 | Balance | 0 |
| 0000950170-25-069824 | 5 | 28 | EQ | 0 | H | Shares Outstanding | us-gaap/2024 | Ending balance, shares | 0 |
| 0000950170-25-069824 | 6 | 2 | CF | 0 | H | Profit Loss | us-gaap/2024 | Net loss | 0 |
| 0000950170-25-069824 | 6 | 4 | CF | 0 | H | Depreciation | us-gaap/2024 | Depreciation | 0 |
| 0000950170-25-069824 | 6 | 5 | CF | 0 | H | Share Based Compensation | us-gaap/2024 | Stock-based compensation, including the issuance of restricted stock | 0 |
| 0000950170-25-069824 | 6 | 6 | CF | 0 | H | In Process Research And Development | 0000950170-25-069824 | Acquired in-process research and development assets | 0 |
| 0000950170-25-069824 | 6 | 8 | CF | 0 | H | Increase Decrease In Collaboration Receivable | 0000950170-25-069824 | Collaboration receivable | 1 |
| 0000950170-25-069824 | 6 | 9 | CF | 0 | H | Increase Decrease In Prepaid Deferred Expense And Other Assets | us-gaap/2024 | Prepaids and other current assets | 1 |
| 0000950170-25-069824 | 6 | 10 | CF | 0 | H | Increase Decrease In Accounts Payable | us-gaap/2024 | Accounts payable | 0 |
| 0000950170-25-069824 | 6 | 11 | CF | 0 | H | Increase Decrease In Accrued Liabilities | us-gaap/2024 | Accrued expenses | 0 |
| 0000950170-25-069824 | 6 | 12 | CF | 0 | H | Increase Decrease In Deferred Revenue | us-gaap/2024 | Deferred collaboration revenue | 0 |
| 0000950170-25-069824 | 6 | 13 | CF | 0 | H | Net Cash Provided By Used In Operating Activities | us-gaap/2024 | Net cash (used in) provided by operating activities | 0 |
| 0000950170-25-069824 | 6 | 15 | CF | 0 | H | Payments To Acquire In Process Research And Development | us-gaap/2024 | Purchase of in-process research and development assets | 1 |
| 0000950170-25-069824 | 6 | 16 | CF | 0 | H | Net Cash Provided By Used In Investing Activities | us-gaap/2024 | Net cash used in investing activities | 0 |
| 0000950170-25-069824 | 6 | 18 | CF | 0 | H | Proceeds From Subscription Receivable | 0000950170-25-069824 | Proceeds from subscription receivable | 0 |
| 0000950170-25-069824 | 6 | 19 | CF | 0 | H | Payment Of Financing Costs Related To Private Placement | 0000950170-25-069824 | Payment of financing costs related to the 2023 Private Placement | 1 |
| 0000950170-25-069824 | 6 | 20 | CF | 0 | H | Proceeds From Stock Options Exercised | us-gaap/2024 | Proceeds from the exercise of stock options | 0 |
| 0000950170-25-069824 | 6 | 21 | CF | 0 | H | Proceeds From Warrant Exercises | us-gaap/2024 | Proceeds from the exercise of warrants | 0 |
| 0000950170-25-069824 | 6 | 22 | CF | 0 | H | Net Cash Provided By Used In Financing Activities | us-gaap/2024 | Net cash provided by financing activities | 0 |
| 0000950170-25-069824 | 6 | 23 | CF | 0 | H | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect | us-gaap/2024 | Net (decrease) increase in cash and cash equivalents | 0 |
| 0000950170-25-069824 | 6 | 24 | CF | 0 | H | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | us-gaap/2024 | Cash and cash equivalents as of beginning of the period | 0 |
| 0000950170-25-069824 | 6 | 25 | CF | 0 | H | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | us-gaap/2024 | Cash and cash equivalents as of end of the period | 0 |
| 0000950170-25-069824 | 6 | 27 | CF | 0 | H | Subscription Receivable Related To Warrant Exercise | 0000950170-25-069824 | Subscription receivable related to warrant exercise | 0 |
| Field Name | Field Description |
|---|---|
| adsh | Accession Number. The 20-character string formed from the 18-digit number assigned by the SEC to each EDGAR submission. |
| report | Represents the report grouping. This field corresponds to the statement (stmt) field, which indicates the type of statement. The numeric value refers to the “R file” as posted on the EDGAR Web site. |
| line | Represents the tag’s presentation line order for a given report. Together with the statement and report field, presentation location, order and grouping can be derived. |
| stmt | The financial statement location to which the value of the “report” field pertains. |
| inpth | Value was presented “parenthetically” instead of in columns within the financial statements. For example: Receivables (net of allowance for bad debts of $200 in 2012) $700. |
| rfile | The type of interactive data file rendered on the EDGAR web site, H = .htm file, X = .xml file. |
| tag | The tag chosen by the filer for this line item. |
| version | The taxonomy identifier if the tag is a standard tag, otherwise adsh. |
| plabel | The text presented on the line item, also known as a “preferred” label. |
| negating | Flag to indicate whether the plabel is negating. |